{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T14:10:38Z","timestamp":1701699038893},"reference-count":52,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib mesylate (IM) is the gold standard for treatment of Chronic Myeloid Leukemia (CML). This study aimed to gain more knowledge of the altered PK, pharmacogenetic factors, and gene expression leading to variable IM levels. Fifty patients with chronic phase-CML were enrolled in this study and divided as 25 responders and 25 non-responders (patients are directly recruited after response assessment). HPLC\/MS\/MS was used to determine trough and peak concentration of imatinib and N-desmethyl imatinib in the blood. PCR-RFLP technique was used to detect IDH1 gene mutation (R132). The median value of IM trough level was significantly higher, the P\/T ratio was significantly lower and the \u03b1-1-acid glycoprotein (AGP) was significantly higher among responders compared to non-responders (P=0.007, 0.009 and 0.048, respectively). Higher N-desmethyl imatinib peak plasma concentration was observed with low mRNA expression of ABCG2 and OCT1 (P=0.01 and 0.037, respectively). IDH1 R132 gene mutation was associated with a significant increase in toxicities (P=0.028). In conclusion, IM trough level, P\/T ratio and AGP was significantly higher in responders. In addition, ABCG2 and OCT1 gene expression may affect the interindividual PK variation. Although a prospective study with a larger patient population is necessary to validate these findings. IDH1 mutation is a predictor of increased toxicity with IM treatment.<\/jats:p>","DOI":"10.1055\/a-1924-7746","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T23:55:07Z","timestamp":1673481307000},"page":"146-155","source":"Crossref","is-referenced-by-count":0,"title":["A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2\/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients"],"prefix":"10.1055","volume":"73","author":[{"given":"Alaa","family":"Sabri","sequence":"additional","affiliation":[{"name":"Egyptian Pharmaceutical Vigilance Center, Egyptian Drug Authority"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervat M.","family":"Omran","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.Abdel","family":"Azim","sequence":"additional","affiliation":[{"name":"Biochemistry Department, Faculty of Pharmacy, Cairo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raafat","family":"Abdelfattah","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha Mahmoud","family":"Allam","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia A.","family":"Shouman","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"ref1","first-page":"164","article-title":"The Biology of Chronic Myeloid Leukemia, N. Engl","volume":"341","author":"S Faderl","year":"1999","journal-title":"J. Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2020005599","article-title":"CML: new tools to answer old questions","volume":"135","author":"G Giotopoulos","year":"2020","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate","volume":"11","author":"J Cortes","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"H Kantarjian","year":"2002","journal-title":"N. Engl. J. Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"A Hochhaus","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","article-title":"Absolute Bioavailability of Imatinib (Glivec\u00ae) Orally versus Intravenous Infusion","volume":"44","author":"B Peng","year":"2004","journal-title":"J. Clin. Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer control"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/bmc.2796","article-title":"Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib","volume":"27","author":"M Birch","year":"2013","journal-title":"Biomed. Chromatogr"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug Transporters and IM Treatment: Implications for Clinical Practice","volume":"17","author":"K Eechoute","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of IM with human organic ion carriers","volume":"14","author":"S Hu","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2217\/pgs-2017-0193","article-title":"Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update","volume":"19","author":"R Ankathil","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clml.2018.02.004","article-title":"Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Sub-trial","volume":"18","author":"S Rinaldetti","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/ijc.29395","article-title":"High IDH1 Expression Is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia","volume":"137","author":"Q Ma","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-019-0173-z","article-title":"Isocitrate dehydrogenase inhibitors in acute myeloid leukemia","volume":"7","author":"X Liu","year":"2019","journal-title":"Biomark. Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1 and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"H Makishima","year":"2011","journal-title":"Blood"},{"key":"ref16","first-page":"1087","article-title":"Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia","volume":"99","author":"S Adnan-Awad","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome \u2013 negative metaphases during CML treatment","volume":"130","author":"G C Issa","year":"2017","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"T P Hughes","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/chromsci\/bmt037","article-title":"LC-MS-MS Determination of Imatinib and N-Desmethyl Imatinib in Human Plasma","volume":"52","author":"Y Zhang","year":"2014","journal-title":"J. Chromatogr. Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.7763\/IJESD.2012.V3.230","article-title":"Influence of ABCB1 C3435T and ABCG2 C421A Gene Polymorphisms in Response to Imatinib Mesylate in Chronic Myeloid Leukemia Patients","volume":"3","author":"A Anthony","year":"2012","journal-title":"Int. J. Environ. Sci. Dev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"S Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial with Chronic Myeloid Leukemia Patients","volume":"22","author":"B Peng","year":"2004","journal-title":"J. Clin. Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e0226552","DOI":"10.1371\/journal.pone.0226552","article-title":"Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia","volume":"14","author":"K Kim","year":"2019","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/10428194.2018.1485907","article-title":"IM trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia, Leuk","volume":"60","author":"H Natarajan","year":"2019","journal-title":"Lymphoma"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/jpps30559","article-title":"Effects of Trough Concentration and Solute Carrier Polymorphisms on IM Efficacy in Chinese Patients with Chronic Myeloid Leukemia","volume":"23","author":"Q Wang","year":"2020","journal-title":"J. Pharm. Pharm. Sci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5581\/1516-8484.20110081","article-title":"Monitoring imatinib plasma concentrations in chronic myeloid leukemia","volume":"33","author":"D H Martins","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on IM trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"N Takahashi","year":"2010","journal-title":"J. Hum. Genet"},{"key":"ref29","first-page":"395","article-title":"Clinical efficacy and safety of imatinib in the management of Ph+chronic myeloid or acute lymphoblastic leukemia in Chinese patients","volume":"7","author":"Y Zhu","year":"2014","journal-title":"OncoTargets Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"Vi313","DOI":"10.1093\/annonc\/mdw375.32","article-title":"Relationship between adherence, drug level and clinical response achieved in patients with chronic myeloid leukemia on IM","volume":"27","author":"M M Omran","year":"2016","journal-title":"Ann. Oncol"},{"key":"ref31","first-page":"1199","article-title":"Early molecular response with IM therapy in chronic myeloid leukemia and its association with baseline white blood cell count and spleen size","volume":"68","author":"A A Wajid","year":"2018","journal-title":"Pak. Armed Forces med. j. (Online)"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term Follow-Up of the French Stop IM (STIM1) Study in Patients with Chronic Myeloid Leukemia","volume":"35","author":"G Etienne","year":"2017","journal-title":"J. Clin. Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of IM cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"D M Ross","year":"2013","journal-title":"Blood"},{"key":"ref34","first-page":"1062","article-title":"Polymorphism and Outcome in Egyptian Chronic Myeloid Leukaemia Patients","volume":"3","author":"O Ghallab","year":"2015","journal-title":"J. Cancer Biol. & Res"},{"key":"ref35","first-page":"130","article-title":"ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to IM and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients","author":"M Tiribelli","year":"2017","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5045\/br.2019.54.1.57","article-title":"ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on IM efficacy","volume":"54","author":"AM L Bedewy","year":"2019","journal-title":"Blood Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with IM response in chronic myeloid leukemia","volume":"28","author":"L N Ni","year":"2011","journal-title":"Med. Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)","volume":"22","author":"L A Doyle","year":"2003","journal-title":"Oncogene"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","article-title":"Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with IM","volume":"32","author":"J Francis","year":"2015","journal-title":"Med. Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to IM in Chronic Myeloid Leukemia","volume":"83","author":"L Wang","year":"2007","journal-title":"Clin. Pharmacol. Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT-1 and resistance to IM","volume":"106","author":"L C Crossman","year":"2005","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","article-title":"Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with IM response in chronic myeloid leukemia","volume":"31","author":"L T De Lima","year":"2014","journal-title":"Med. Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","article-title":"The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia","volume":"121","author":"A Giannoudis","year":"2013","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI67266","article-title":"Isocitrate dehydrogenase mutations in leukemia","volume":"123","author":"A S McKenney","year":"2013","journal-title":"J. Clin. Investig"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"C Roche-Lestienne","year":"2011","journal-title":"Leukemia"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/fon-2017-0523","article-title":"The role of IDH mutations in acute myeloid leukemia","volume":"14","author":"G Montalban-Bravo","year":"2018","journal-title":"Future Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-16-2628","article-title":"Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"23","author":"Q Xu","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1200\/JCO.2009.27.6899","article-title":"Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor","volume":"28","author":"K Wagner","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2402991","article-title":"Dose-limiting dermatological toxicity secondary to IM mesylate (STI571) in chronic myeloid leukaemia","volume":"17","author":"D Milojkovic","year":"2003","journal-title":"Leukemia"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of IM in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"L Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"ref51","first-page":"30","article-title":"IM induced toxicity and its influence on cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia","author":"H Natarajan","year":"2019","journal-title":"Ann. Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.3109\/10428194.2014.885515","article-title":"Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia","volume":"55","author":"H Malhotra","year":"2014","journal-title":"Leuk Lymphoma"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1924-7746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T13:57:01Z","timestamp":1701698221000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1924-7746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":52,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,3,6]]},"published-print":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1924-7746","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}